Proteomic analysis of extracellular vesicle released by MCF7 cells in the absence of the tetraspanins CD9, CD81 or CD63
Ontology highlight
ABSTRACT:
INSTRUMENT(S): timsTOF Pro
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Extracellular Vesicle, Breast Cancer Cell Line, Cell Line Cell
SUBMITTER: 
Cédric Pionneau
LAB HEAD: Eric RUBINSTEIN
PROVIDER: PXD042940 | Pride | 2023-08-03
REPOSITORIES: Pride
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| 1DE02.mzTab.gz | Mztab | |||
| 1DE03-1.mzTab.gz | Mztab | |||
| 1DE03-2.mzTab.gz | Mztab | |||
| 1DE04.mzTab.gz | Mztab | |||
| 1DE05.mzTab.gz | Mztab |
Items per page: 5 1 - 5 of 72 |
Similar Datasets
Project description:RNA-seq was performed on cultured human induced pluripotent cell derived cardiomyocytes (iPSC-CMs). There are four groups, with three samples per group: H1,H2,H3. Negative control. Healthy, normoxic iPSC-CMs D1,D2,D3. Positive control. iPSCs cultured under hypoxic (0-1% O2) for 48h with 2% v/v PBS as vehicle control EV1,EV2,EV3. Treatment 1. iPSCs cultured under hypoxic (0-1% O2) for 48h, with cardiac stromal cell derived extracellular vesicles, provided at a dose of 67ng/µl (2% v/v) EV21, EV23, EV24. Treatment 2 iPSCs cultured under hypoxic (0-1% O2) for 48h, with bone marrow mesenchymal stromal cell (BM-MSC) derived extracellular vesicles, provided at a dose of 67ng/µl (2% v/v) All EVs were isolated from cultured human cells using sequential centrifugation methods. Cells were cultured using commercial EV-depleted FBS to avoid contamination of bovine EVs. EVs were validated for CD81, CD9, ALIX positivity, and visualised by cryoEM. Particle to protein ratios were not different between cardiac and bone marrow EV isolates. Therefore EV doses were standardised so that the same dose by protein (67ng/µl) and EV number (~2,000 EVs per iPSC-CM) were added.
2024-10-02 | E-MTAB-13966 | biostudies-arrayexpress
Project description:EWI-2 (IgSF8) plays a novel, bifunctional role in melanoma cells. EWI-2 inhibits migration, metastasis, EMT-like changes, and CD271-dependent invasion in multiple melanoma cell lines. On the other hand, EWI-2 supports melanoma cell proliferation, survival, and xenograft growth. Consistent with these results, EWI-2 levels were elevated in human malignant melanoma, but not in metastatic melanoma samples. Altered melanoma cell functions, caused by EWI-2 ablation, are almost entirely dependent on enhanced TRF-M-NM-21 signaling, and also require contributions from tetraspanin proteins CD9 and CD81. In melanoma cells lacking EWI-2, tetraspanins CD9 and CD81 enhance TRF-M-NM-21 signaling by facilitating TM-NM-2R-2M-bM-^HM-^RTM-NM-2R-1 receptor complex formation. When EWI-2 is present, CD9 and CD81 are diverted into EWI-2 complexes, and thus TRF-M-NM-21 signaling is inhibited. 4 samples = 2 Control + 2 EWI-2 KD.
2013-06-15 | E-GEOD-47978 | biostudies-arrayexpress
Project description:EWI-2 (IgSF8) plays a novel, bifunctional role in melanoma cells. EWI-2 inhibits migration, metastasis, EMT-like changes, and CD271-dependent invasion in multiple melanoma cell lines. On the other hand, EWI-2 supports melanoma cell proliferation, survival, and xenograft growth. Consistent with these results, EWI-2 levels were elevated in human malignant melanoma, but not in metastatic melanoma samples. Altered melanoma cell functions, caused by EWI-2 ablation, are almost entirely dependent on enhanced TRF-β1 signaling, and also require contributions from tetraspanin proteins CD9 and CD81. In melanoma cells lacking EWI-2, tetraspanins CD9 and CD81 enhance TRF-β1 signaling by facilitating TβR-2−TβR-1 receptor complex formation. When EWI-2 is present, CD9 and CD81 are diverted into EWI-2 complexes, and thus TRF-β1 signaling is inhibited.
2013-06-15 | GSE47978 | GEO
Project description:Extracellular vesicles (EVs) have gained attention as a mechanism facilitating intercellular as well as interkingdom communication during host-microbe interactions. Recently we showed that upon infection, host polymorphonuclear leukocytes produce antifungal EVs targeting the clinically important fungal pathogen Aspergillus fumigatus; however, the small size of EVs complicates their tracking and functional analysis. We employed a more tractable, reporter-based system to label host alveolar epithelial cell-derived EVs and enable their visualization and tracking during in vitro A. fumigatus interaction. Proteome analysis of the cargo of these EVs confirmed the EV marker proteins, tetraspanins CD63, CD9, and CD81, and revealed limited antifungal components, which was corroborated by mito-GFP fungal killing assays. Fusion of the EV marker proteins with a nanoluciferase (NLuc) and a green fluorescent protein (GFP) facilitated their relative quantification by luminescence and visualization by fluorescence signal. The use of an NLuc fused with a GFP is advantageous as it allows quantification and visualisation of EVs simultaneously without additional external manipulation. Using this system, visualisation of EVs was possible using confocal laser scanning microscopy and revealed the ability of host cell-derived EVs to associate with A. fumigatus hyphae. In conclusion, we have created a series of tools to better define the complex interplay of host-derived EVs with microbial pathogens.
2024-11-13 | PXD050398 | Pride
Project description:We developed a column-based CD9 antibody-immobilized HPLC immunoaffinity (CD9-HPLC-IAC) technology for EV isolation from a microliter-scale of serum for downstream proteomic analysis. The CD9-HPLC-IAC method achieved EV isolation from 40 μL of serum in 30 min with a yield of 8.0×109 EVs. Proteomic analysis showed that the common exosomal markers such as CD63, CD81, CD82, Alix, and TSG101 were all identified in EVs. Statistical analysis of EV protein content showed that the top 10 serum proteins in EVs was significantly decreased by using the CD9-HPLC-IAC method compared to the ultracentrifugation (UC) (p=0.001) and size exclusion chromatography (SEC) (p=0.009), and apolipoproteins significantly reduced 4.8-fold compared to the SEC method (p<0.001). The result demonstrated the potential of the CD9-HPLC-IAC method for efficient isolation and proteomic characterization of EVs from a micro-scale volume of serum.
2022-10-14 | PXD027025 | Pride
Project description:The ability to isolate extracellular vesicles (EVs) from blood is vital in the development of EVs as disease biomarkers. Both serum and plasma can be used, but few studies have compared these sources in terms of the quantity and type of EVs that are obtained. The aim of this study was therefore to determine the presence of different subpopulations of EVs in plasma and serum. Blood samples were collected from healthy subjects, from which plasma and serum were isolated in parallel. ACD-A or EDTA tubes were used for the collection of plasma, while serum was obtained in clot activator tubes. We previously developed a method utilising a combination of density cushion and size exclusion chromatography to isolate EVs from plasma with minimal contamination of lipoprotein particles. In the current study, we applied this method to both EDTA-plasma and serum. In addition, EVs were isolated by a combination of density cushion and density gradient or by bead immune capturing (anti-CD63, anti-CD9, and anti-CD81 beads). The subpopulations of EVs were analysed by nanoparticle tracking analysis, Western blot, single particle interferometric reflectance imaging sensing, conventional and nano flow cytometry, magnetic bead enzyme-linked immunosorbent assay, and mass spectrometry.This study shows that a larger number of CD9+ EVs are present in EDTA-plasma compared to ACD-plasma and serum, and the presence of CD41a on theses EVs suggests that they are released from platelets. Furthermore, only a small number of EVs in blood were double positive for CD63 and CD81. The CD63+ EVs were enriched in serum, while CD81+ vesicles were the rarest subpopulation in both plasma and serum. Together, these findings show that multiple subpopulations of EVs are present in blood including CD9+/CD41a+, CD9+/CD63+/CD41+, CD63+/CD41a+, CD63+/CD9+/CD81−, CD81+/CD9+/CD63−, and CD9+/CD63+/CD81+ and that their presence is dissimilar in EDTA-plasma, ACD-plasma and serum.
2022-05-20 | PXD026863 | Pride
Project description:While of growing interest in pancreatic cancer (PC) field, the stromal-tumor cells crosstalk lags behind in terms of biomarkers and therapeutic options improving the clinical armamentarium. Knowledge on cellular communications was drastically enhanced following the discovery of extracellular vesicles (EVs), a powerful process of intercellular exchanges. We previously described a new stromal-tumor cell crosstalk mediated by Cancer-Associated Fibroblasts (CAFs)-derived ANXA6+-EVs, supporting pancreatic cancer cell aggressiveness in hostile areas of PC. In this study, using mass spectrometry analyses to investigate CAFs-derived EVs' cargo, we report that CD9 is a key member of the ANXA6/LRP1/TSP1 complex present in PC-associated CAFs-derived ANXA6+-EVs. We determined that CD9 is expressed by PC-associated CAFs in vivo as well as in vitro following physiopathologic culture conditions. Targeting CD9 impaired CAFs-derived ANXA6+-EVs uptake by pancreatic cancer cells, which consequently decreases their migratory abilities. Signaling pathway arrays highlighted p38/MAPK as activated in pancreatic cancer cells following CAFs-derived ANXA6+/CD9+-EVs uptake. The use of CD9 blocking antibody, p38 siRNA or chemical inhibitors impaired pancreatic cancer cells abilities following incubation with CAFs-derived ANXA6+/CD9+-EVs. Finally, we revealed CD9 expression as an independent poor-prognosis marker in human PC samples. Collectively our data highlight the key role of CD9 in CAFs-derived ANXA6+-EVs internalization by pancreatic cancer cells and the consequent, and mandatory, activation of p38/MAPK pathway to foster their migratory abilities. Measuring the oncogenic CAFs-derived ANXA6+/CD9+-EVs then limiting their action on pancreatic cancer cells abilities might be a promising option for PC stratification and treatment.
2022-08-21 | PXD023165 | Pride
Project description:Background: Acute coronary syndromes (ACS) are associated with aberrant gene expression and epigenetic mechanisms. In particular, de novo DNA methylation is typically linked to gene silencing, but its role in heart disease remains not fully understood. Extracellular vesicles (EVs) are active components in cellular communication for their ability to carry a plethora of signalling biomolecules, thus representing a promising new diagnostic/therapeutic approach in cardiovascular diseases (CVDs). Indeed, there is the need of novel biomarkers for ACS prediction and timely detection. Purpose: We hypothesized that specific epigenetic signals can be carried by EVs. In this regard, we isolated and characterized circulating EVs from ACS patients and evaluated their potential role to influence DNA methylation in target cells. Methods: Circulating EVs were recovered, by ultracentrifugation, from plasma samples of 19 ACS patients and 50 healthy subjects (HS). Nanoparticle tracking analysis (NTA) and western blot (WB) were used to confirm the EVs integrity and purity. Peripheral blood mononuclear cells (PBMCs) of volunteer donors were treated with both ACS and HS derived EVs and genomic DNA was extracted to perform epigenome wide analysis through Reduced Representation Bisulfite Sequencing. ShinyGO, PANTHER, and STRING tools were interrogated to perform GO and PPI network analyses. Flow Cytometry, qRT-PCR, and WB analysis were also performed to evaluate and validate both intra-vesicular and intra-cellular signals. Results: Plasma ACS-derived EVs showed a significant up-regulation of DNA methyltransferases (DNMTs) gene expression levels as compared to HS (P<0.001). Specifically, de novo methylation transcripts, as DNMT3A and DNMT3B were significantly increased in plasma ACS-EVs. DNA methylation analysis of PBMCs from volunteer donors treated with HS- and ACS-derived EVs showed that RNF166 and CCND3 genes resulted the most hyper- and hypo-methylated, respectively, after by ACS-EV treatment. In addition, PPI network analysis specifically evidenced the subnetwork with SRC, as a hub gene, connecting it to NOTCH1, FOXO3, CDC42, IKBKG, RXRA, DGKG, known as important genes already involved in the onset of CVDs. Surprising, other novel genes, BAIAP2, SYP, CHL1, and SHB, which were hypomethylated, were found significantly overexpressed in PBMCs (P<0.005), underlying the fundamental modulating properties of EV cargo in atherosclerosis. Conclusions: These findings support the significant role of ACS plasma-derived EVs, inducing de novo DNA methylation signals, and modulating specific signaling pathways in target cells.
2023-04-03 | E-MTAB-11641 | biostudies-arrayexpress
Project description:Neural stem cell (NSC)-based therapies can exploit the inherent pathotropism of NSCs to deliver neurotrophic factors for cell replacement therapies and to stimulate endogenous neurogenesis to permanently repair damaged brain tissue after brain injury. Despite studies on the protective/restorative functions of NSCs and their extracellular vesicles (EVs), a major impediment to advancing this approach to late-stage preclinical studies and clinical practice has been the lack of molecular characterization of NSCs and NSC-EV cargo composition. To fill this knowledge gap, we characterized therapeutically relevant human fetal NSC lines expressing the L-MYC gene (LMNSC01, LMNSC02) and their EVs using single-cell RNA sequencing (scRNAseq) and proteomic analyses. LMNSC01 cells differentiate into neurons and glial cells, including oligodendrocytes, and LMNSC02 mostly differentiate into neurons and oligodendrocyte progenitor cells (OPCs) under undirected differentiation in vitro. scRNAseq analysis indicates that LMNSC01 and LMNSC02 populations are homogenous, expressing not only NSC markers such as SOX2 and nestin, but also doublecortin (DCX), OPC marker O1, and astrocyte progenitor marker vimentin. LMNSC01 cells were enriched in biomarkers for astrocytes, excitatory neurons, glial cells, and OPCs, and LMNSC02 in inhibitory neurons, glial cells and OPCs. Using Single Extracellular VEsicle Nanoscopy, we quantified the size, shape, and content of tetraspanins (CD9, CD63, and CD81) for EVs secreted by cultured LMNSC01 and LMNSC02 cells. Both cell lines produced largely circular EVs; compared to EVs from LMNSC01 cells, those from LMNSC02 cells had on average higher detected tetraspanin content and larger diameter. We also quantified protein, RNA concentration, particle number, and batch-to batch variability for each EV. Our EV cargo global proteomics results suggest that LMNSC02 cells are enriched in processes involved in neuron development, neuron protection, synaptic transmission, and axon development, while EVs derived from LMNSC01 cells were more enriched in RNA processing. Finally, we identified neuroprotective properties of LMNSC-EVs in a brain organoid model of methotrexate-induced brain tissue toxicity. Our data suggest that LMNSC01 and LMNSC02 cell lines have distinct utilities, highlighting the need for molecular characterization to identify the cell lines and EVs with the highest therapeutic potential for various neurological conditions.
2024-11-21 | GSE281914 | GEO
Project description:Neural stem cell (NSC)-based therapies can exploit the inherent pathotropism of NSCs to deliver neurotrophic factors for cell replacement therapies and to stimulate endogenous neurogenesis to permanently repair damaged brain tissue after brain injury. Despite studies on the protective/restorative functions of NSCs and their extracellular vesicles (EVs), a major impediment to advancing this approach to late-stage preclinical studies and clinical practice has been the lack of molecular characterization of NSCs and NSC-EV cargo composition. To fill this knowledge gap, we characterized therapeutically relevant human fetal NSC lines expressing the L-MYC gene (LMNSC01, LMNSC02) and their EVs using single-cell RNA sequencing (scRNAseq) and proteomic analyses. LMNSC01 cells differentiate into neurons and glial cells, including oligodendrocytes, and LMNSC02 mostly differentiate into neurons and oligodendrocyte progenitor cells (OPCs) under undirected differentiation in vitro. scRNAseq analysis indicates that LMNSC01 and LMNSC02 populations are homogenous, expressing not only NSC markers such as SOX2 and nestin, but also doublecortin (DCX), OPC marker O1, and astrocyte progenitor marker vimentin. LMNSC01 cells were enriched in biomarkers for astrocytes, excitatory neurons, glial cells, and OPCs, and LMNSC02 in inhibitory neurons, glial cells and OPCs. Using Single Extracellular VEsicle Nanoscopy, we quantified the size, shape, and content of tetraspanins (CD9, CD63, and CD81) for EVs secreted by cultured LMNSC01 and LMNSC02 cells. Both cell lines produced largely circular EVs; compared to EVs from LMNSC01 cells, those from LMNSC02 cells had on average higher detected tetraspanin content and larger diameter. We also quantified protein, RNA concentration, particle number, and batch-to batch variability for each EV. Our EV cargo global proteomics results suggest that LMNSC02 cells are enriched in processes involved in neuron development, neuron protection, synaptic transmission, and axon development, while EVs derived from LMNSC01 cells were more enriched in RNA processing. Finally, we identified neuroprotective properties of LMNSC-EVs in a brain organoid model of methotrexate-induced brain tissue toxicity. Our data suggest that LMNSC01 and LMNSC02 cell lines have distinct utilities, highlighting the need for molecular characterization to identify the cell lines and EVs with the highest therapeutic potential for various neurological conditions.
2024-11-21 | GSE281915 | GEO